Interaction of B7-H1 on intrahepatic cholangiocarcinoma cells with PD-1 on tumor-infiltrating T cells as a mechanism of immune evasion

Journal of Surgical Oncology

Volumn 100, Issue 6, 2009, Pages 500-504

  Yufu, Ye ^a   Lin, Zhou ^a   Xiaojun, Xie ^a   Guoping, Jiang ^a   Haiyang, Xie ^a   Shusen, Zheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

B7 H1; Intrahepatic cholangiocarcinoma; PD 1; Tumor infiltrating lymphocytes

Indexed keywords

B7 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; MEMBRANE PROTEIN; PROGRAMMED CELL DEATH PROTEIN 1; PROTEIN B7H1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER STAGING; CARCINOMA CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; MALE; NICK END LABELING; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DIFFERENTIATION; UPREGULATION;

ANTIGENS, CD; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LYMPHOCYTE COUNT; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; TUMOR ESCAPE; UP-REGULATION;

EID: 70350335367     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21376     Document Type: Article

References (27)

1. Patel T: Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353-1357. (Pubitemid 32496970)
2. Yamashita Y, Taketomi A, Morita K, et al.: The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: Retrospective analysis of 60 patients. Anticancer Res 2008;28:2353-2359.
3. Endo I, Gonen M, Yopp AC, et al.: Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008;248:84-96.
4. Yachimski P, Pratt DS: Cholangiocarcinoma: Natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 2008;42:178-190.
5. Finn OJ: Cancer immunology. N Engl J Med 2008;358:2704-2715.
6. Chiou SH, Sheu BC, Chang WC, et al.: Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005;67:35-50. (Pubitemid 41415554)
7. Zang X, Allison JP: The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res 2007;13:5271-5279. (Pubitemid 47510350)
8. Dong H, Chen L: B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003;81:281-287. (Pubitemid 36718324)
9. Wu C, Zhu Y, Jiang J, et al.: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19-24. (Pubitemid 44316588)
10. Thompson RH, Kuntz SM, Leibovich BC, et al.: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-3385.
11. Geng L, Huang D, Liu J, et al.: B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression. J Cancer Res Clin Oncol 2008;134:1021-1027.
12. Nakanishi J, Wada Y, Matsumoto K, et al.: Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56:1173-1182. (Pubitemid 46763932)
13. Dong H, Strome SE, Salomao DR, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800. (Pubitemid 34887242)
14. Mantovani A, Romero P, Palucka AK, et al.: Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet 2008;371:771-783.
15. Inman BA, Frigola X, Dong H, et al.: Costimulation, coinhibition and cancer. Curr Cancer Drug Targets 2007;7:15-30.
16. Miescher S, Whiteside TL, Moretta L, et al.: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 1987;138:4004-4011. (Pubitemid 17078287)
17. Rabinowich H, Suminami Y, Reichert TE, et al.: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-284. (Pubitemid 26384127)
18. Piras F, Colombari R, Minerba L, et al.: The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase. Cancer 2005;104:1246-1254. (Pubitemid 41278960)
19. Prall F, Duhrkop T, Weirich V, et al.: Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-816. (Pubitemid 38903073)
20. Schumacher K, Haensch W, Roefzaad C, et al.: Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 2001;61:3932-3936. (Pubitemid 32720953)
21. Hamanishi J, Mandai M, Iwasaki M, et al.: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365. (Pubitemid 46364164)
22. Nakano O, Sato M, Naito Y, et al.: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: Clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-5136. (Pubitemid 32681545)
23. Dong H, Zhu G, Tamada K, et al.: B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 2004;20:327-336. (Pubitemid 38388234)
24. Beswick EJ, Pinchuk IV, Das S, et al.: Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4+ CD25+ FoxP3+ regulatory T cells. Infect Immun 2007;75:4334-4341.
25. Kitazawa Y, Fujino M, Wang Q, et al.: Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007;83:774-782. (Pubitemid 46569197)
26. Azuma T, Yao S, Zhu G, et al.: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111:3635-3643.
27. Dong H, Zhu G, Tamada K, et al.: B7-H1. a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.